SUNMO: PHASE III TRIAL OF MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN VERSUS RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN IN RELAPSED/REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMA
Bibliographic record
Abstract
Introduction: Aggressive non-Hodgkin lymphomas (aNHL) are a diverse group of neoplasms, of which diffuse large B-cell lymphoma (DLBCL) is the most common subtype (Thandra, 2021). Patients (pts) with relapsed/refractory (R/R) DLBCL after one prior therapy who are unable to receive, or relapsed after, an autologous stem cell transplant (ASCT) and/or chimeric antigen receptor T-cell therapy have a poor prognosis (Salles, 2019; Di Blasi, 2022). Mosunetuzumab (Mosun) is an off-the-shelf CD20xCD3 T-cell engaging bispecific antibody that redirects T cells to eliminate malignant B cells (Sun, 2015), with promising efficacy and safety as a single agent, as shown in a Phase I trial in pts with B-cell NHL, including aNHL (Budde, 2022). Mosun has also shown promising safety and efficacy in combination with polatuzumab vedotin (Pola), a CD79b targeted antibody-drug conjugate that delivers the microtubule-disrupting agent monomethyl auristatin E directly to B cells (Dornan, 2009), in a Phase Ib/II trial in pts with R/R aNHL (Budde, ASH 2021). Encore Abstract—previously submitted to ASCO 2023 The research was funded by: SUNMO (NCT05171647) is sponsored by F. Hoffmann-La Roche Ltd. Third-party medical writing assistance, under the direction of all authors, was provided by Martha Warren MSci of Ashfield MedComms, an Inizio company, and was funded by F. Hoffmann-La Roche Ltd. Keywords: aggressive B-cell non-Hodgkin lymphoma, immunotherapy Conflicts of interests pertinent to the abstract J. Westin Consultant or advisory role Novartis, Kite/Gilead, Janssen, ADC Therapeutics, Iksuda Therapeutics, BMS/Celgene/Juno, AstraZeneca, Genentech/Roche, Abbvie, Merck, Monte Rosa Therapeutics, Morphosys/Incyte, Seattle Genetics Research funding: Janssen, Genentech, Novartis, Kite/Gilead, BMS, AstraZeneca, Morphosys/Incyte, ADC Therapeutics A. J. Olszewski Employment or leadership position: Brown Physicians, LLC Consultant or advisory role Genmab, Schrodinger Research funding: Genentech, Adaptive Biotech, Precision Bio, Kymera Therapeutics, Schrodinger W. S. Kim Research funding: Sanofi, Beigene, Boryong, Roche, Kyowa-kirin, Donga H. Shin Employment or leadership position: Pusan National University Hospital D. Leão Employment or leadership position: Legal Person (Beneficencia Portuguesa De São Paulo) Other remuneration: Travel, accommodation, expenses—Janssen, Novartis, Takeda, AMGEN, Roche, Libbs, ABBVIE, AstraZeneca, Zodiac, Kite/Gilead; Leadership—Chronic lymphoproliferative diseases clinic at Beneficencia Portuguesa de Sao Paulo L. Norasetthada Employment or leadership position: Chiang Mai University Research funding: MSD, Astra Zeneca, Roche E. Rego Employment or leadership position: Rede D ́Or/University of São Paulo Consultant or advisory role Astellas, Abbvie Honoraria: Astellas, Abbvie, Pfizer, Novartis Research funding: Astellas Other remuneration: Travel, accommodation, expenses—Astellas, Abbvie, Pfizer, Novartis H. Wu Employment or leadership position: Genentech; Ended employment in past 24 months—Amgen S. Yin Employment or leadership position: Genentech Inc. Stock ownership: Genentech Inc. Other remuneration: Patents, royalties, other intellectual property—Genentech Inc.; Travel, accommodation, expenses—Genentech Inc. C. L. Batlevi Employment or leadership position: Roche/Genentech Stock ownership: Roche/Genentech S. Pham Employment or leadership position: Roche Canada E. Penuel Employment or leadership position: Genentech Stock ownership: Genentech J. Jing Employment or leadership position: Genentech M. C. Wei Employment or leadership position: Genentech Stock ownership: Roche Other remuneration: Travel, accommodation, expenses—Genentech/Roche L. E. Budde Consultant or advisory role Roche/Genentech, Kite/Gilead, Novartis, BeiGene Research funding: Merck, Amgen, MustangBio, AstraZeneca Other remuneration: Patents, royalties, other intellectual property—CCR4 CAR T cells for treatment of patients with CCR4 positive cancer, CD33CAR for treatment of patients with CD33+ acute myeloid leukemia; Travel, accommodation, expenses—Roche/Genentech, Kite/Gilead
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.000 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".